Olanzapine orally disintegrating tablets (Zyprexa Zydis^R) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: An open-label prospective study

References

• Arranz B, Duenas RM, Centeno M, Ramirez N, Salavert J, Del Moral E. Lower weight gain with orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol Clin Exp 2007; 22: 11–15
   PubMedGoogle Scholar
• Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003; 23: 342–348
   PubMed Web of Science ®Google Scholar
• Citrome L. Treatment noncompliance with orally disintegrating olanzapine tablets. Can J Psychiatry 2004; 49: 412–413
   PubMedGoogle Scholar
• De Haan L, Van Amelsvoort T, Rosien K, Linszen D. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 2004; 175: 389–390
   PubMedGoogle Scholar
• Escobar R, San L, Pérez V, Olivares JM, Polavieja P, López-Carrero C, et al. Effectiveness results of olanzapine in acute psychotic patients with agitation in the emergency room setting: Results from NATURA study. Actas Esp Psiquiatr 2008; 36: 151–157
   PubMed Web of Science ®Google Scholar
• Hatta K., Kawabata T, Yoshida K, Hamakawa H, Wakajima T, Furuta K, et al. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients. Gen Hosp Psychiatry 2008; 30: 367–371
   PubMed Web of Science ®Google Scholar
• Hovens JE, Dries PJT, Melman CTM, Wapenaar CTM, Loonen AJM. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: A prospective, comparative, open-label study. J Psychopharmacol 2005; 19: 51–57
   PubMed Web of Science ®Google Scholar
• Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988; 23: 99–110
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Hill AL, Liu H, Kollack-Walker S. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacol 2003; 6: 97–102
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Roychowdhury SM, Milton DR, Hill AL. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry 2001; 62(Suppl 2)17–21
   PubMed Web of Science ®Google Scholar
• Lambert M, Huber CG, Naber D, Schacht A, Wanger TT, Hundemer HP, et al. Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder. Pharmacopsychiatry 2008; 41: 182–189
   PubMedGoogle Scholar
• Lindenmayer JP, Brown E, Baker RW, Schuh LM, Shao L, Tohen M, et al. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr Res 2004; 68: 331–337
   PubMed Web of Science ®Google Scholar
• Pascual JC, Perez V, Martin JLR, Safont G, Puigdemont D, Alvarez E. Olanzapine orally-disintegrating tablet in severe psychotic agitation: A naturalistic study. Actas Esp Psiquiatr 2007; 35: 47–51
   PubMedGoogle Scholar
• San L, Casillas M, Ciudad A, Gilaberte I. Olanzapine orally disintegrating tablet: A review of efficacy and compliance. CNS Neurosci Ther 2008; 14: 203–214
   PubMed Web of Science ®Google Scholar
• Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley CJ, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999; 156: 79–87
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Beasley CMJ, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997; 154: 457–465
   PubMed Web of Science ®Google Scholar
• Tornatore FL. Orally disintegrating antipsychotics may promote compliance and adherence in patients wirth schizophrenia. J Clin Psychiatry 2005; 66: 1493–1494
   PubMedGoogle Scholar
• Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley CJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407–418
   PubMed Web of Science ®Google Scholar
• Turczynski J, Bidzan L, Staszewska-Malys E. Olanzapine in the treatment of agitation in hospitalized patients with schizophrenia and schizoaffective and schizofreniform disorders. Med Sci Monit 2004; 10: PI74–80
   PubMedGoogle Scholar
• Yoshimura R, Nakamura J, Shinkai K, Goto M, Yamada Y, Kaji K, et al. An open study of risperidone liquid in the acute phase of schizophrenia. Hum Psychopharmacol Clin Exp 2005; 20: 243–248
   PubMed Web of Science ®Google Scholar